Use of electronic data to improve risk adjustment for antibiotic utilization metrics
Use of electronic data to improve risk adjustment for antibiotic utilization metrics
批准号:
9981718
负责人:
ANTHONY D HARRIS
金额:
$30.42万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-30 至 2021-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Each year in the United States at least 2 million people become infected with antibiotic-resistant bacteria and
at least 23,000 people die as a direct result. Overuse of antibiotics is a key factor driving the emergence of
antibiotic-resistant bacteria. This has led federal agencies to recommend acute care facilities have
antimicrobial stewardship programs and record antimicrobial utilization data using the National Quality Forum
(NQF)-endorsed Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network
(NHSN) Antimicrobial Use Measure. Many believe that it is inevitable that antimicrobial utilization data will be
used to judge performance of hospitals and as a pay-for-performance outcome. The gap in knowledge is that
current risk adjustment methods used by the CDC for antimicrobial utilization data are sub-optimal because
methods to adjust for patient comorbid conditions do not exist. Our long-term goal is to improve the quality and
validity of publicly reported metrics for healthcare quality including healthcare-associated infection and
antimicrobial utilization data. The overall objective of this proposal is to determine which comorbid conditions
should be used for risk adjustment of antimicrobial utilization data. Our central hypothesis is that comorbid
conditions identified by ICD codes that are easily obtained electronically from hospitals across the United
States can be used to improve risk adjustment of antimicrobial utilization metrics. The rationale for this
proposal is the need for further advancement in risk adjustment methodology for antimicrobial utilization
metrics. Now is the ideal time to establish appropriate risk adjustment measures for antimicrobial use because
CMS has not yet incorporated antibiotic use into its value-based purchasing system. Comorbid conditions are a
logical starting point as they have been proven to be significant predictors of other infectious disease outcomes
and are easy to obtain. We plan to test our central hypothesis and, thereby, accomplish the objective of this
proposal by pursuing the following specific aims: Aim 1: Perform a cohort study of adult patients admitted to
multiple hospitals across the United States to determine which electronically obtained comorbidities are risk
factors for different antibiotic utilization metrics. Aim 2: Demonstrate that risk adjustment using comorbid
conditions affect hospital rankings of antimicrobial utilization. The expected outcome of this research is the
identification of comorbid conditions using ICD codes for that can be used to risk adjust antimicrobial utilization
data. The implementation of these by the CDC and CMS will lead to more valid publically available data. The
significance of our research is that it will identify easily available electronically comorbid conditions that could
be used to better risk adjust these antibiotic utilization metrics. The proposed research is innovative in that no
one has explored the use of ICD codes for risk adjustment of antimicrobial utilization data. This work
challenges the existing paradigm of risk adjustment of antimicrobial utilization metrics. In addition, this project
has the potential to significantly impact antimicrobial utilization metrics and pay-for-performance methods.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1093/cid/ciaa570
发表时间:
2021-07-15
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
作者:
[Goodman KE, Cosgrove SE, Pineles L, Magder LS, Anderson DJ, Dodds Ashley E, Polk RE, Quan H, Trick WE, Woeltje KF, Leekha S, Harris AD]
通讯作者:
Harris AD
DOI:
10.1093/cid/ciaa1127
发表时间:
2021-12-06
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
作者:
[Goodman KE, Pineles L, Magder LS, Anderson DJ, Ashley ED, Polk RE, Quan H, Trick WE, Woeltje KF, Leekha S, Cosgrove SE, Harris AD]
通讯作者:
Harris AD
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events
-
批准号:10466723
-
项目类别:
-
资助金额:$82.4万
-
财政年份:2021
-
负责人:ANTHONY D HARRIS
-
依托单位:
Targeted Contact Precaution Use to Prevent MRSA Transmission
-
批准号:10178338
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:ANTHONY D HARRIS
-
依托单位:
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events
-
批准号:10403419
-
项目类别:
-
资助金额:$140.68万
-
财政年份:2021
-
负责人:ANTHONY D HARRIS
-
依托单位:
Targeted Contact Precaution Use to Prevent MRSA Transmission
-
批准号:10689825
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:ANTHONY D HARRIS
-
依托单位:
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events
-
批准号:10650204
-
项目类别:
-
资助金额:$142.4万
-
财政年份:2021
-
负责人:ANTHONY D HARRIS
-
依托单位:
Epicenters for the Prevention of Healthcare-Associated Infections (HAIs); Cycle II Multicenter Program Studies
-
批准号:9753064
-
项目类别:
-
资助金额:$71.58万
-
财政年份:2018
-
负责人:ANTHONY D HARRIS
-
依托单位:
Use of electronic data to improve risk adjustment for antibiotic utilization metrics
-
批准号:9574676
-
项目类别:
-
资助金额:$39.2万
-
财政年份:2018
-
负责人:ANTHONY D HARRIS
-
依托单位:
Epicenters for the Prevention of Healthcare-Associated Infections (HAIs); Cycle II Multicenter Program Studies
-
批准号:10199880
-
项目类别:
-
资助金额:$90.0万
-
财政年份:2018
-
负责人:ANTHONY D HARRIS
-
依托单位:
Epidemiology of CRE and MRSA transmission: patient and organism factors
-
批准号:9986208
-
项目类别:
-
资助金额:$5.3万
-
财政年份:2016
-
负责人:ANTHONY D HARRIS
-
依托单位:
Epidemiology of CRE and MRSA transmission: patient and organism factors
-
批准号:9330060
-
项目类别:
-
资助金额:$58.04万
-
财政年份:2016
-
负责人:ANTHONY D HARRIS
-
依托单位:
Does Universal Glove and Gown use decrease carbapenem-resistant Gram-negative bacteria
-
批准号:8934663
-
项目类别:
-
资助金额:$48.25万
-
财政年份:2015
-
负责人:ANTHONY D HARRIS
-
依托单位:
Epicenters for the Prevention of Healthcare Associated Infections (HAI) - Cycle II
-
批准号:9076457
-
项目类别:
-
资助金额:$218.11万
-
财政年份:2015
-
负责人:ANTHONY D HARRIS
-
依托单位:
Does Universal Glove and Gown use decrease carbapenem-resistant Gram-negative bacteria
-
批准号:9145196
-
项目类别:
-
资助金额:$47.55万
-
财政年份:2015
-
负责人:ANTHONY D HARRIS
-
依托单位:
Does Universal Glove and Gown use decrease carbapenem-resistant Gram-negative bacteria
-
批准号:9348611
-
项目类别:
-
资助金额:$20.85万
-
财政年份:2015
-
负责人:ANTHONY D HARRIS
-
依托单位:
Use of electronic data to improve risk adjustment for hospital infection rates
-
批准号:8560048
-
项目类别:
-
资助金额:$46.76万
-
财政年份:2013
-
负责人:ANTHONY D HARRIS
-
依托单位:
Use of electronic data to improve risk adjustment for hospital infection rates
-
批准号:9052713
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2013
-
负责人:ANTHONY D HARRIS
-
依托单位:
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
-
批准号:8416369
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2009
-
负责人:ANTHONY D HARRIS
-
依托单位:
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
-
批准号:7659719
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2009
-
负责人:ANTHONY D HARRIS
-
依托单位:
K24 Clinical research in Antimicrobial Resistance and Hospital Epidemiology
-
批准号:8700018
-
项目类别:
-
资助金额:$17.61万
-
财政年份:2009
-
负责人:ANTHONY D HARRIS
-
依托单位:
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology
-
批准号:8211047
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2009
-
负责人:ANTHONY D HARRIS
-
依托单位:
国内基金
海外基金
基于循证医学本体论的临床元数据语言研究
-
批准号:30972549
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2009
-
负责人:徐维
-
依托单位:
双原子分子高激发振转能级的精确研究
-
批准号:10774105
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2007
-
负责人:孙卫国
-
依托单位:
基于安全多方计算的抗强制电子选举协议研究
-
批准号:60773114
-
项目类别:面上项目
-
资助金额:28.0万元
-
批准年份:2007
-
负责人:仲红
-
依托单位: